SIMCERE PHARMACEUTICAL GROUP, ADS
SCR
SCR was delisted on the 23rd of December, 2013.
0 hedge funds and large institutions have $0 invested in SIMCERE PHARMACEUTICAL GROUP, ADS in 2021 Q2 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
100% less funds holding
Funds holding: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $26.9K → $0 (-$26.9K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIC
Archer Investment Corporation
Carmel,
Indiana
|
-$26.9K |
SCR Hedge Fund Activity: Q2 2021 in Review
0 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in SIMCERE PHARMACEUTICAL GROUP, ADS (SCR) for Q2 2021, worth a combined $0 — down 100% from $26.9K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of SCR and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was Archer Investment Corporation, exiting entirely with an estimated $26.9K sold.
- 0 institutional investors held SIMCERE PHARMACEUTICAL GROUP, ADS (SCR) as of Q2 2021, down from 1 in Q1 2021.
- Funds reported $0 of SIMCERE PHARMACEUTICAL GROUP, ADS stock for Q2 2021, down 100% quarter-over-quarter.
- 0 funds opened new SIMCERE PHARMACEUTICAL GROUP, ADS positions in Q2 2021 and 1 closed out, a net change of -1 holder.
- The largest SIMCERE PHARMACEUTICAL GROUP, ADS seller in Q2 2021 was Archer Investment Corporation, an estimated $26.9K sold.
Based on aggregated 13F filings for Q2 2021.